Part 2: Breast implant-associated anaplastic large-cell lymphoma: Recommendations for future research on prevention

Background. Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a newly defined clinical entity. However, much of the research around this topic is based on low levels of evidence prognostic studies. Part 2 follows on our part 1 article discussion on potential BIA-ALCL risk factors, and provides clinically relevant suggestions for further study. Recommendations. From the available research, we were able to identify several potential strategies to reduce BIA-ALCL risk. These recommendations were graded according to the grade practice recommendations suggested by Burns et al. These strategies include: avoiding Allergan BIOCELL textured implants; using sterile surgical technique; patient screening; use of anti-inflammatory drugs; and the avoidance of implants in genetically susceptible individuals. Conclusion. Owing to the lack of studies with a high level of evidence on BIA-ALCL prevention, few strong recommendations for clinical application can be made at this point. However, our article identifies areas in need of further study.